Elevated levels of EZH2 is linked to bad outcome in synovial sarcoma as per the following article:
http://www.ncbi.nlm.nih.gov/pubmed/23110793
According to the following article, EZH2 inhibitors could work as anti-angiogenic and anti-metastatic therapy:
http://www.ncbi.nlm.nih.gov/pubmed/22711031
Now, we just have to wait another 10 years to see such drug in clinical trials...